Navigation Links
Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
Date:9/5/2012

CARLSBAD, Calif., Sept. 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:

  • Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 11:15 a.m. ET in New York
  • Morgan Stanley Global Healthcare Conference on Tuesday, September 11, 2012 at 2:00 p.m. ET in New York

A live audio webcast of the presentations will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

 

 

 


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
2. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
3. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
4. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
5. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
6. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
7. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. UCF nanoparticle discovery opens door for pharmaceuticals
10. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
11. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... , ... Experienced periodontist in Eden Prairie, MN, Dr. Andres Sanchez, offers a ... PIEZOSURGERY® technology. PIEZOSURGERY uses ultrasonic vibrations to gently cut bone in the mouth ... implants, especially when the implants need to be placed in a sensitive area of ...
(Date:5/15/2020)... ... May 14, 2020 , ... ... cell banks and hMSC bioprocess systems, today announced the launch of its ... extracellular vesicles (EVs). RoosterCollect™-EV-CC is the only system designed with hMSC-EV product ...
(Date:5/15/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches ... Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has ... Miller and Sentien’s management team. , Mr. Ganz has more than 30 ...
(Date:5/14/2020)... ... May 13, 2020 , ... In collaboration with Sartorius, ... in the Life Science Lab . The comprehensive information source was created for ... and liquid handling to contamination control. , The content hub features the latest ...
Breaking Biology Technology:
(Date:5/26/2020)... ... May 26, 2020 , ... ... R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology company developing ... engagers and TCR-based therapeutics, has implemented Genedata Biologics ® within their ...
(Date:5/21/2020)... ... 20, 2020 , ... Law Enforcement has always been a highly stressful career ... positions of these men and women put them constantly in harm’s way both from ... Officers have always had to face very high daily stress. Now, COVID-19 introduces another ...
(Date:5/14/2020)... ... May 14, 2020 , ... ... medical sales representatives, found the 2019 average medical sales rep total compensation increased ... shadowed by uncertainties amid the COVID-19 global crisis. , The MedReps 2020 Salary ...
Breaking Biology News(10 mins):